

Nicholas, M. K., Lukas, R. V., Jafri, N. F., Faoro, L., & Salgia, R. (2006). Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas. *Clinical Cancer Research*, 12(24), 7261-7270.

Norrby, K. (1997). Angiogenesis: new aspects relating to its initiation and control. *Apmis*, 105(1-6), 417-437.

Noseworthy, J. H., Wolinsky, J. S., Lublin, F. D., Whitaker, J. N., Linde, A., Gjorstrup, P., & Sullivan, H. C. (2000). Linomide in relapsing and secondary progressive MS Part I: Trial design and clinical results. *Neurology*, 54(9), 1726-1733.

Nyberg, P., Xie, L., & Kalluri, R. (2005). Endogenous inhibitors of angiogenesis. *Cancer research*, 65(10), 3967-3979.

O'Hare, T., Deininger, M. W., Eide, C. A., Clackson, T., & Druker, B. J. (2011). Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. *Clinical Cancer Research*, 17(2), 212-221.

O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., ... & Folkman, J. (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. *cell*, 88(2), 277-285.

O'Reilly, M. S., Pirie-Shepherd, S., Lane, W. S., & Folkman, J. (1999). Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. *Science*, 285(5435), 1926-1928.

Ozao-Choy, J., Ma, G., Kao, J., Wang, G. X., Meseck, M., Sung, M., ... & Chen, S. H. (2009). The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. *Cancer research*, 69(6), 2514-2522.